This webinar will focus on the implications of the Inflation Reduction Act (IRA) on value proposition development and the evidence needed for drugs launching in 2027-2028 that plan to seek reimbursement from Medicare. Join PRECISIONvalue’s Andrew Cournoyer and Precision Value & Health’s Ross Maclean for this value packed webinar.
The Inflation Reduction Act will definitely impact established wholesale acquisition costs and rebates. Now that the Medicare bid season is upon us, how can manufacturers prepare? PRECISIONvalue expert Andrew Cournoyer, SVP of the Access Experience Team, explains in this must-see video.
When you squeeze a balloon, the air goes somewhere. Same with the cost of drugs. PRECISIONvalue expert Andrew Cournoyer, SVP of the Access Experience Team, explains the anticipated fallout from the Inflation Reduction Act in this 90-second video.
Biosimilars deliver dramatic reductions in drug costs—and the Inflation Reduction Act is supposed to encourage their uptake. But lower prices mean lower reimbursement, disincentivizing providers. PRECISIONvalue expert Amy Martin explains how in this 2-minute video.
How will the Inflation Reduction Act effect manufacturers of both originator drugs and biosimilars? According to PRECISIONvalue expert Amy Martin, a range of unintended consequences may impact pricing, innovation—and ultimately the therapies available to patients. Watch this short video to see why.
Precision is proud to have published our inaugural 2023 Environmental, Social and Governance (ESG) Report, reflecting the company’s ongoing efforts to do better for our people, in our practices, and with the broader community at large. This year’s report shares key achievements, performance metrics, and steps we have taken to enhance sustainability throughout the company, including:
· Engaging internal and external stakeholders in our company’s first ESG materiality assessment to identify and prioritize our material issues
· Defining Precision’s approach to ESG in our company’s ESG Strategy Statement · Creating a three-year strategic ESG Roadmap for advancing our performance across environmental, social, and governance issues · Initiating energy efficiency projects and standards across our facilities
· Implementing implicit bias training for our Executive Leadership Team and Human Resources leaders
· Contributing volunteer hours by over 425 employees and over $250,000 in donations to more than 70 charitable foundations and causes
In September, the American Association for Cancer Research reported that hospitals are facing the worst chemotherapy drug shortage crisis the US has ever seen. Anshul Mangal, President of Project Farma, sat down with AJMC to address the primary reasons for the current cancer drug shortages and how Project Farma is helping to address these challenges.
There are approximately 7000 rare diseases affecting 30 million individuals in the United States and up to 250 million individuals worldwide. The unmet medical need for individuals living with these conditions has made this a very active area for research and development. Precision’s Phil Cyr discusses how patients and caregivers can be a catalyst for rare disease innovation.
This article was originally published on This Month in Transformative Medicine on October 17, 2023
The current standard of cancer care has saved many lives, but these methods often come with incredibly difficult side effects. Advancements in technology have brought new options to cancer care that hope to provide meaningful outcomes while minimizing the impact to the patient’s quality of life.
In this white paper Anshul Mangal, President of Project Farma (PF) & Precision ADVANCE, and Sumit Verma, Co-founder and Partner at Orchestra Life Sciences, discuss the power and potential of radioligand therapies and its impact on the treatment of a number of cancers.
How can our industry address the root causes for the current cancer drug shortages, and how can we prepare and avoid these shortages? Anshul Mangal, President of Project Farma and Precision ADVANCE, sat down with PharmExec.com to share answers.